Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 119 for “"AAV9"”.
-
Exploring modifiers in spinal muscular atrophy : the power of AAV9
… paralysis, and eventually death. We utilize scAAV9, a viral vector, as a tool for introducing heterogeneous genes as a method for delivery. We and others have shown that delivery of full length SMN1 to the �delta 7� SMA mouse model fully rescues the disease. Therefore, we employ scAAV9 to …
-
Uncovering Peripheral Organ Defects in Spinal Muscular Atrophy: Insights from AAV9-SMN Gene Therapy
… or intracerebroventricular (ICV) delivery of scAAV9-cba-SMN on the mice. Smn²ᴮᐟ⁻ mice displayed several peripheral defects prior to motor neuron loss. ICV injections increased SMN in peripheral organs and the CNS while IV administration increased SMN in peripheral tissues only, largely omitting …
-
AAV9-NeuroD1 as a Therapeutic Approach for Functional Restoration after Acute and Subacute Spinal Cord Injury
… unclear. As such, we employed a Cre-dependent, AAV9 DIO-based delivery strategy to selectively drive NeuroD1 expression in reactive astrocytes for SCI, specifically evaluating titer-dependent functional and neuroprotective outcomes when delivered in the acute or subacute stage of injury. …
-
Correction of AB Variant GM2 Gangliosidoses Using AAV9 Viral Vector Gene Therapy in a Mouse Model
… a one-time treatment of single stranded (ss) AAV9/GM2A viral vector therapy at a dose of 1 x 1014 vector genomes per kilogram of mouse and to see at least biochemical reduction in GM2 ganglioside storage in both the short- and long-term treated cohorts. ssAAV9/GM2A plasmid was created and …
-
Tropismo del vector de terapia génica AAV9 en el envejecimiento fisiológico : hacia una intervención biogerontológica molecular
… de genes juegan un papel importante. El vector AAV9 presenta la capacidad de atravesar la barrera hematoencefálica en roedores neonatos y adultos, además de transducir múltiples órganos periféricos, convirtiéndolo en una herramienta muy eficaz para una intervención biogerontológica molecular. Se …
-
MODULATION OF THE AAV9 GALACTOSE BINDING POCKET YIELDS NOVEL GENE THERAPY VECTORS AND PREDICTS CROSS-SPECIES GLYCAN PROFILES
… residues in the galactose-binding pocket of the AAV9 capsid, Y446, N470 and W503. Two rounds of screening in mice identified the XRH family of AAV variants (Y446X, N470R, and W503H), each exhibiting reduced liver transduction paired with enhanced cardiac transduction. The strongest of these …
-
Intrathecal Aav9.trastuzumab Tumor Prophylaxis And Treatment In A Murine Xenograft Model Of Her2+ Breast Cancer Brain Metastases
… developed an adeno-associated virus serotype 9 (AAV9) vector to express trastuzumab in vivo after a single intrathecal (IT) injection. IT vector administration in an orthotopic Rag1-/- murine xenograft model of HER2+ BCBM led to a significant increase in median survival and attenuated brain tumor …
-
From bench to therapy : exploring mouse models and AAV9 gene therapy for Charcot-Marie-Tooth disease type 2E
… single-stranded adeno-associated vector type 9 (AAV9) to rescue disease pathology in the novel CMT2E models. We delivered 1 x10¹² vector genomes to the CMT2E mice at postnatal day (P) 0 and 1 and identified rescue in electrophysiology, nerve morphology, muscle pathology, and motor function. This …
-
OPTIMIZATION OF AAV9 GENE THERAPY FOR SPINAL MUSCULAR ATROPHY WITH RESPIRATORY DISTRESS TYPE 1 USING IN VIVO DISEASE MODELS
… of two adeno‐associated virus serotype 9 (AAV9)-IGHMBP2 vectors, carrying different promoters, by administering them intracerebroventricularly in SMARD1 mice model (nmd), during the presymptomatic phase of the disease at postnatal day 1. This comparison allowed us to determine which is the …
-
Histopathological Assessment of Liver and Spleen Following Intracortical AAV9–NeuroD1 Administration in a Non-Human Primate Model of Ischaemic Stroke
… delivery of adeno-associated virus serotype 9 (AAV9) encoding neurogenic differentiation factor 1 (NeuroD1) is being investigated as a regenerative strategy for structurally injured cortex. Although focal administration is intended to concentrate vector exposure within the central nervous …
-
Der Transkriptionsfaktor EB (Tfeb) begünstigt unter chronischem myokardialen Stress die Entstehung einer Herzinsuffizienz
… Durch Adeno-assoziierte virale Vektoren Typ 9 (AAV9) wurde Tfeb in den Kardiomyozyten von erwachsenen C57BL/6J Mäusen überexprimiert (AAV9-Tfeb), wobei die Kardiomyozyten-spezifische Expression durch Verwendung eines spezifischen Promoters (Myosin Leichtketten (MLC) 2v Promoter) erfolgte. …
-
Expanding the scope of adeno-associated-virus vectors
… platforms of use. Here, we introduce novel AAV9-based capsid variants displaying small peptide insertions attempting to alter the natural tropism for effective transduction of retinal cells after less invasive intravitreal (IVT) administration. Previously heparan-sulfate proteoglycan (HSPG) …
-
MUTAGENESIS OF AAV CAPSID PROTEINS FOR ENHANCED TRANSDUCTION OF CARDIAC CELL TYPES
Background: Adeno- associated virus serotype 9 (AAV9) has a high transduction efficiency for cardiac tissues, along with liver, skeletal muscle, pancreatic tissue, and the eye, versus other AAV serotypes. Unfortunately, nonspecific targeting to the intended tissue can result in the need for use of …
-
AAV9-mediated (Pro)renin Receptor Antagonism Reduces High Fat Diet Induced Hyperglycemia and Hepatic Steatosis in Mouse Model of Non-alcoholic Fatty Liver Disease
… delivered by adeno-associated virus, serotype 9 (AAV9) vector via systemic route, based on the findings of a prior experiment in this study. Here we validated AAV-PHP.eB and AAV9 in Neuro-2A cells, and confirmed AAV-PHP.eB and AAV9 expression in the brain and in non-CNS tissues. In addition, we …
-
Assessing the potential of rAAV9 systemic gene therapy for GM2 gangliosidoses using a Sandhoff mouse model
… utility of systemic adeno-associated virus 9 (AAV9)-based gene delivery in treating GM2 gangliosidoses, we evaluated the therapeutic outcome of a single intravenous injection of recombinant AAV9 encoding the complementing Hexb gene in a Sandhoff mouse model. We showed prolonged survival, …
-
Optimization of adeno-associated virus production for misexpression of Dlk1-Dio3 noncoding RNAs in cardiac and skeletal muscle analysis in vivo
… from the imprinted Dlk1-Dio3 locus. Five AAV9 viruses were produced, each containing one of the following transgenes: 1) human Meg3 cDNA for overexpression of this long noncoding RNA, 2) Meg3-specific short hairpin RNA for knockdown analysis, 3) eGFP cDNA to demonstrate AAV9 tissue …
-
Controlling Transgene Expression in the Central Nervous System For MRI-Guided Focused Ultrasound Delivery of Adeno-Associated Virus
… of non-BBB penetrating AAV serotypes, or AAV9 at a dose approximately 50-fold lower than the systemic minimum, to targeted regions of the CNS. First, AAV9 distribution in the spinal cord tested whether physical differences in the BSCB compared the to the BBB cause alterations in MRIgFUS …
-
IN VIVO AND IN VITRO EVALUATION OF THE COMBINATION OF RNA INTERFERING AND GENE THERAPY FOR TREATING MITOFUSIN2-RELATED DISEASES
… (CSF) delivery using adeno-associated virus 9 (AAV9). Results: We demonstrated the correct silencing of endogenous MFN2 and replacement with an exogenous copy of the functional wild-type gene in cells. This approach significantly rescues the CMT2A MN phenotype in vitro, stabilizing the altered …
-
CHARACTERIZATION OF THE AAV-PHP.B CAPSID AND ITS INTERACTION WITH THE LY6A RECEPTOR: IMPLICATIONS FOR RECEPTOR-TARGETED VECTOR ENGINEERING
… graft the Ly6a binding epitope from its native AAV9 context into an AAV1 backbone and test the performance of the engineered variants in vivo. We then comprehensively explore the impact of receptor affinity on the systemic targeting and endothelial penetration properties of AAV vectors, using a …
Page 1 of 6